VEGFA and breast cancer: In the NSABP B-40 clinical trial evaluating bevacizumab (anti-VEGF targeted therapy) efficiency in advanced BC, the addition of neoadjuvant plus adjuvant bevacizumab lead to a significant increase in overall survival, especially in hormone-receptor-positive BC patients [84].